Early Phase 1 N=54 Cognitive Rehabilitation in Parkinson's Disease
Parkinson's Disease
Primary: Reaction Time and Variability for Movement Task — 1013.858333; 994.94875; 979.2450877; 910.9120833 milliseconds
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Early Phase 1 N=15 n-Acetylcysteine and Cocaine
Cocaine Abuse · Cocaine Dependence
Primary: Number of Times Cocaine Was Selected in the Presence of a Monetary Reward Alternative — 1.0; 0.1; 3.4; 3.9 Number of Cocaine Choices
Early Phase 1 N=11 Phendimetrazine and Cocaine
Cocaine Use Disorder
Primary: Peak Systolic Pressure — 115.4; 121.3; 123.4; 122.1 mm Hg
Early Phase 1 N=6 Pilot Study of Lucentis Combined With Proton Beam Irradiation in Treating Wet Age-related Macular Degeneration
Age-related Macular Degeneration
Primary: Incidence and Severity of Ocular Adverse Events — 0 number of adverse events
Early Phase 1 N=12 Oxytocin Effects on Cardiac Electrophysiology
Cardiac Arrhythmia
Primary: Change in Electrophysiology Measure of AH Interval — 12.7; -1.5 milliseconds
Early Phase 1 N=170 Effect of Metformin on Early Pregnancy Loss in Pregnant Women With Polycystic Ovarian Syndrome
Polycystic Ovary Syndrome
Primary: Miscarriage Rate — 9; 35 participants
Early Phase 1 N=19 A Study of Dog Adoption in Veterans With Posttraumatic Stress Disorder (PTSD)
Posttraumatic Stress Disorder (PTSD)
Primary: Change in PTSD Checklist (PCL-5) Score Between Baseline and 3-month Follow-up — -15.20; -7.77 units on a scale — p=0.141
Early Phase 1 N=18 Acceptance and Commitment Therapy for the Inpatient Treatment of Psychosis
Psychotic Disorders
Primary: Brief Psychiatric Rating Scale (Overall & Gorham, 1962) — -8.0; -11.6 percentage of total possible change
Early Phase 1 N=25 Trigeminal Nerve Stimulation for Attention Deficit Hyperactivity Disorder (ADHD)
Attention-Deficit/Hyperactivity Disorder
Primary: ADHD-IV Rating Scale (ADHD-RS) — 32.6 units on a scale
Early Phase 1 N=25 Study to Assess Safety and Immune Response of Stage IIB-IV Resected Melanoma After Treatment With MAGE-A3 ASCI
Melanoma
Primary: Number of Participants With Treatment-related Adverse Events as a Measure of Safety and Tolerability — 1; 0; 4; 2 participants
Early Phase 1 N=11 7 Day Continuous Parathyroid Hormone IV Infusion
Osteoporosis · Bone Diseases, Endocrine · Hyperparathyroidism
Primary: Participants With Dose Limiting Toxicity — 0; 2 participants
Early Phase 1 N=101 Dose Response Study of Aerobic Exercise in Older Adults
Alzheimer's Disease
Primary: Visuospatial Processing — -.02; .19; .08; .29 units on a scale
Early Phase 1 N=14 One Week Parathyroid Hormone-related Protein (PTHrP) IV Dose Escalation Study
Osteoporosis · Humoral Hypercalcemia of Malignancy · Hyperparathyroidism
Primary: Dose Limiting Toxicity (DLT) — 0; 0; 2; 2 participants
Early Phase 1 N=33 Tango for Treatment of Motor and Non-motor Manifestations in Parkinson's Disease.
Parkinson's Disease
Primary: Severity of PD (Unified Parkinson Disease Rating Scale - UPDRS, 2008 Version) — 24.7; 30.5; 24.4; 30.2 units on a scale
Early Phase 1 N=50 Advanced Comprehensive Diabetes Care for Veterans With Poorly-Controlled Diabetes
Diabetes
Primary: Diabetes Control — 10.7; 10.2; 10.3; 9.1 percentage of glycosylated hemoglobin — p=0.012